Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China
Description
In recent years, urgent unmet medical needs due to the COVID-19 pandemic have accelerated the application of mRNA technology in vaccine development, leading to some of the first approvals of mRNA vaccines in human history by regulatory agencies
